镰状细胞病骨髓的定量MRI评估:与溶血及临床严重程度的关系
本研究为横断面研究,纳入48例镰状细胞病(SCD)患者和48名年龄、性别、体重匹配的健康对照,采用Dixon技术定量腰椎和骨盆骨髓脂肪分数(FFDix)。结果显示SCD患者FFDix低于对照,HbSS亚型及高溶血程度者更低;髂骨FFDix检测高溶血程度的AUC为0.824。
要点
- Dixon MRI可定量骨髓脂肪分数,SCD患者FFDix降低。
- 髂骨FFDix≤16.75%时检测高溶血程度AUC=0.824。
- FFDix有望作为无创生物标志物用于SCD评估和随访。
关键影像表现/征象
- SCD患者骨髓FFDix低于健康对照。
- HbSS亚型患者FFDix低于HbSC亚型。
- 高溶血程度患者FFDix更低。
- 使用羟基脲的HbSC高溶血患者FFDix更低。
诊断标准与关键数值
- 高溶血程度定义:Hb≤10 g/dl、LDH≥325 U/l、网织红细胞≥3%、TB≥1.2 mg/dl。
- 检测高溶血程度:髂骨FFDix≤16.75%,AUC=0.824,p<0.001。
- 检测高溶血程度:股骨头FFDix≤46.7%,AUC=0.775,p=0.001。
- 检测高溶血程度:腰椎FFDix≤7.8%,AUC=0.755,p=0.002。
临床应用与阅片要点
- 可尝试在SCD患者腰椎和骨盆MRI中增加Dixon序列定量FFDix。
- 阅片时关注髂骨、股骨头和腰椎骨髓FFDix值,低于阈值提示高溶血风险。
- FFDix可作为SCD随访中评估疾病严重度的辅助指标。
局限性
- 为横断面研究,无法确定因果关系。
- 单中心研究,样本量有限。
- 未报告重复性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate bone marrow fat fraction using the Dixon technique (FFDix) of magnetic resonance imaging (MRI) as a potential biomarker of haemolysis and clinical severity in the overall assessment and follow-up of sickle cell disease (SCD) patients.
MATERIAL AND METHODS: The present study was a cross-sectional study in which healthy individuals and SCD patients (matched for age, sex, and weight) were subjected to MRI of the lumbar spine and pelvis to quantify FFDix in the bone marrow using the Dixon technique. SCD severity was analysed by clinical and laboratory data, and an online calculator. A high degree of haemolysis was defined using the cut-off values haemoglobin (Hb) ≤10 g/dl, lactate dehydrogenase (LDH) ≥325 U/l, reticulocytes ≥3% and total bilirubin (TB) ≥1.2 mg/dl. Pearson's correlation, receiver operating characteristic (ROC) curve and binary logistic regression analysis were performed.
RESULTS: Forty-eight SCD patients (26 homozygous: HbSS and 22 compound heterozygous: HbSC) and 48 healthy individuals participated in the study. FFDix was lower in SCD patients than in the control group, showing even lower values in the HbSS subtype and patients with a higher degree of haemolysis. HbSC patients with a higher degree of haemolysis using hydroxyurea (medium dosage 9.8 mg/kg/day) had lower FFDix. ROC curves and odds ratios for detecting patients with a higher degree of haemolysis at the different FFDix measurement sites demonstrated excellent performance: iliac bones (cut-off ≤16.75%, AUC = 0.824, p<0.001), femoral heads (cut-off ≤46.7%, AUC = 0.775, p=0.001), lumbar vertebrae (cut-off ≤7.8%, AUC = 0.755, p=0.002).
CONCLUSION: Decreased FFDix is indicative of higher degree of haemolysis and SCD severity with great potential as a non-invasive biomarker contributing to the overall assessment and follow-up of SCD patients.
引用
- Lins, Salmon, Amorim de Souza, et al. Quantitative MRI evaluation of bone marrow in sickle cell disease: relationship with haemolysis and clinical severity. Clin Radiol. 2022. PMID: 36623977. doi:10.1016/j.crad.2022.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。